Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Industry

Unicycive's phosphate binder gets March 2027 FDA review target after manufacturer switch

The US regulator has taken up the refiled oxylanthanum carbonate application, which now names a new manufacturer, leaving the small-cap company with a dated path to a possible launch.

16 Nov 2026 · Unicycive Therapeutics, Inc. UNCY · Company news

Unicycive Therapeutics now has a date on which its dialysis drug could win US approval: 25 March 2027. That is the target the FDA has set for its review of the refiled application for oxylanthanum carbonate, a phosphate binder for hyperphosphatemia in patients on dialysis. The company disclosed the acceptance with its third-quarter 2026 results.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Unicycive Therapeutics, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More IndustryAll →